Using immunoblotting, we investigated sera of 60 patients with atopic dermatitis, 12 patients with helminth infections and 36 nonallergic controls, for anti-IgE autoantibodies. We found IgG anti-IgE autoantibodies in 62% of the atopies, 42% of the patients with parasitosis and 11% of the controls. IgG anti-IgE occurred most often (94%) in patients with atopic dermatitis plus additional atopic disorder, such as allergic asthma and rhinoconjunctivitis. In parallel, we found a significantly higher occurence of IgG anti-IgE in the patients with high IgE levels compared to patients with low IgE levels (p < 0.0005). The predominant subclasses of anti-IgE autoantibodies were IgG1 and IgG3 in atopy and parasitosis. In the controls, we found IgG4 and IgG3 anti-IgE, but no IgG1 autoantibodies. The frequency of IgG2 anti-IgE was very low; it occurred in 2 patients only. Prevalence and IgG subclass distribution of anti-IgE autoantibodies was found to be different for patients with atopic dermatitis, parasitic infection and for controls.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.